加载中
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
常规交易时段
US$3.72
−US$0.04 · -1.06%
盘中时间采用ET。市场数据可能有所延迟。
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
日内区间
当前US$3.72
52周区间
当前US$3.72
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
46
合理估值
情绪
56
多空交织
风险
75
高风险
动量
18
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
日内区间
当前US$3.72
52周区间
当前US$3.72
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 29.91万 USD | — | — | — | — |
| 毛利 | 29.91万 USD | — | — | — | — |
| 研究与开发 | 32.22万 USD | 159.87万 USD | 197.49万 USD | 632.49万 USD | 433.64万 USD |
| 销售、一般及管理费用 | 902.4万 USD | 521.2万 USD | 633.89万 USD | 981.01万 USD | 828.19万 USD |
| 营业费用 | 934.62万 USD | 681.07万 USD | 831.39万 USD | 1613.5万 USD | 1261.83万 USD |
| 利息收入 | 44.29万 USD | 127.59万 USD | 164.9万 USD | 33.5万 USD | 7110 USD |
| 折旧和摊销 | 3616 USD | 5580 USD | 6347 USD | 5714 USD | 4966 USD |
| 营业利润 | −904.72万 USD | −681.07万 USD | −831.39万 USD | −1613.5万 USD | −1261.83万 USD |
| 净利润 | −2873.74万 USD | −1276.85万 USD | −603.85万 USD | −557.4万 USD | −1261.12万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Extended Market ETFVXF
Vanguard Morningstar Total Stock Market ETFVTI
iShares Micro-Cap ETFIWC
U.S. Micro Cap Portfolio ETFDFMCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
